# Diana Saraceni

> Diana Saraceni is a Series A investor at Panakes Partners backing Therapeutics and Biotechnology. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Panakes Partners](https://shizune.co/investors/profile/panakes-partners)
- Location: Milan, Italy
- Total investments: 5
- Last investment: May 2025
- Lead investor: 60%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/diana-saraceni-74994/

Diana Saraceni is a Series A investor at Panakes Partners in Milan focused on Therapeutics and Biotechnology. Diana has been a Venture Capitalist for the last twelve years and has invested all over in Europe, with a particular focus in the medical devices. Previously, Diana was Senior Advisor at Lazard Investment Banking. In Lazard she was part of the Technology Team and primarily worked on M&A transactions and IPOs. Prior to Lazard, Diana spentseveral years as strategic consultant with A.T.Kearney in Milan and London. Diana was/is part of several national and international selection committees. Diana graduated in Engineering, received an MBA from LUISS of Rome and is fluent in Italian, English, French and Spanish.She enjoys backpack travelling, dancing, sailing and auteur cinema but her main passion is her family which she co-founded with her husband Renato a few years ago. The three most recent additions to the team are Francesca, Massimo e Riccardo. She is totally handicapped when it comes to both cooking and orientation, despite several attempts to improve.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 3 | 60% |
| Biotechnology | 3 | 60% |
| Medical Device | 3 | 60% |
| Medical | 1 | 20% |
| Health Care | 1 | 20% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 40% |
| Series B | 2 | 40% |
| Venture - Series Unknown | 1 | 20% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| Italy | 2 | 40% |
| France | 1 | 20% |
| The Netherlands | 1 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Salvia BioElectronics | Salvia BioElectronics develops innovative neuromodulation devices aimed at treating migraines. The company focuses on creating a paper-thin implant that delivers gentle electrical pulses to specific nerves, helping to alleviate migraine symptoms. Salvia BioElectronics is dedicated to advancing its technology through ongoing research and developmentefforts. With recent funding, the company works to bring its migraine therapy to market, offering a new approach to pain management for patients. The emphasis is on improving patient outcomes through effective neuromodulation therapy. | $60.1M | Series B | May 27, 2025 |  |
| TENSIVE | Tensive is a biomedical startup established in 2012 to develop innovative prostheses aiming to offer a natural breast reconstruction or augmentation.Tensive is a biomedical startup established in 2012 to develop innovative prostheses aiming to offer a natural breast reconstruction or augmentation. | $14.6M | Series A | Jan 29, 2025 |  |
| CarThera | CarThera designs and develops innovative therapeutic ultrasound-based medical devices for treating brain disorders since.The company’s proprietary device called SonoCloud® is an intracranial ultrasound implant that temporarily opens the blood-brain barrier (BBB) and allows a significantly increased concentration of therapeutic molecules to reachthe brain. | $41.1M | Series B | Jun 27, 2023 |  |
| Diadem | Diadem is an innovative blood-based test exploiting a proprietary antibody targeting a specific conformation of p53 protein. | $11M | Venture - Series Unknown | Mar 28, 2022 |  |
| Salvia BioElectronics | Salvia BioElectronics develops innovative neuromodulation devices aimed at treating migraines. The company focuses on creating a paper-thin implant that delivers gentle electrical pulses to specific nerves, helping to alleviate migraine symptoms. Salvia BioElectronics is dedicated to advancing its technology through ongoing research and developmentefforts. With recent funding, the company works to bring its migraine therapy to market, offering a new approach to pain management for patients. The emphasis is on improving patient outcomes through effective neuromodulation therapy. | $31M | Series A | Sep 22, 2020 |  |

5 of 5 investments shown.

## Co-investors
- [BOM](https://shizune.co/investors/profile/brabantse-ontwikkelings-maatschappij-bom) — VC Fund, 2 deals together
- [Dolby Family Ventures](https://shizune.co/investors/profile/dolby-family-ventures) — VC Fund, 2 deals together
- [European Innovation Council](https://shizune.co/investors/profile/european-innovation-council) — VC Fund, 2 deals together
- [Inkef](https://shizune.co/investors/profile/inkef-capital) — VC Fund, 2 deals together
- [Innovation Industries](https://shizune.co/investors/profile/innovation-industries) — VC Fund, 2 deals together
- [SHS Capital](https://shizune.co/investors/profile/shs-gesellschaft-fr-beteiligungsmanagement-mbh) — VC Fund, 2 deals together

## About Panakes Partners

VC Fund · Milano, Italy

Panakès Partners is a Venture Capital firm, based in Milan, which invests in the most ambitious companies and teams, developing revolutionary technologies and products, in the field of life sciences, aiming to improve the lives of people around the world. Panakès, founded in 2015 by Fabrizio Landi, Alessio Beverina and Diana Saraceni, has 250million under management.

5 contacts available at Panakes Partners.

| Name | Title | Profile |
| --- | --- | --- |
| Alessio Beverina | Co-Founder & General Partner | https://shizune.co/investors/profile/alessio-beverina |
| Fabrizio Landi | Founder and Managing Partner | https://shizune.co/investors/profile/fabrizio-landi |
| Barbara Castellano | Partner | https://shizune.co/investors/profile/laura-iris-ferro |
| Diana Saraceni | General partner | https://shizune.co/investors/profile/diana-saraceni |
| Rob Woodman | Partner | https://shizune.co/investors/profile/rob-woodman |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Diana Saraceni invest in?

Diana Saraceni invests primarily in Therapeutics, Biotechnology and Medical Device startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in Italy. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Diana Saraceni last invest?

The most recent investment recorded for Diana Saraceni closed in May 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co